Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fabrizio

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
Blood|September 9, 2021
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemiaJenna Rossoff, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|July 30, 2025
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR AnalysisHemalatha G Rangarajan, Prakash Satwani, Megan M Herr, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
Blood|September 9, 2021
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemiaJenna Rossoff, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|July 30, 2025
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR AnalysisHemalatha G Rangarajan, Prakash Satwani, Megan M Herr, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Pageof 7